Johnson & Johnson Oncology Sellside Event Highlights

This report covers key updates from JNJ's post-ASCO oncology sellside event, highlighting potential in prostate cancer, lung cancer, and multiple myeloma therapeutics. The company aims for over $50bn in oncology revenue by 2030.

Key Takeaways

• 1.JNJ highlighted key updates across their oncology franchise, with a long-term revenue potential of $50bn+ by 2030.
• 2.Management emphasized the potential for Erleada in high-risk, localized prostate cancer following positive data from the ASCO plenary session.
• 3.The company reported rapid launch acceleration for Inlexzo in bladder cancer following the April permanent J-code.

Table of Contents

• Johnson & Johnson (JNJ): Oncology Sellside Event Highlights ASCO and Other Updates
• Key Topics and Takeaways
• Valuation and Risks
• Disclosure Appendix

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial